11 results about "Ion transporter" patented technology

This invention belongs to the field of pharmaceutical technology and discloses small organic molecules for reducing copper overload toxicity and their applications. Specifically, it discloses four small organic molecules for reducing copper overload toxicity and methods for doing so. These four small organic molecules are not copper chelators and do not reduce intracellular copper levels, thus not affecting the activity of copper-related enzymes. Furthermore, these four small organic molecules are not copper ion transporters and do not transport copper into cells, thus not exacerbating the cytotoxicity of copper overload.

The invention belongs to the technical field of medicines, and discloses an organic small molecule for reducing copper overload toxicity and application thereof. The invention specifically discloses four small organic molecules for reducing the overload toxicity of copper and a method for reducing the overload toxicity of copper. The four small organic molecules are not copper chelating agents and cannot reduce the copper level in cells, so that the copper-related enzyme activity cannot be influenced. Meanwhile, the four small organic molecules are not copper ion transporters and cannot transport copper into cells, so that the cytotoxicity of copper overload cannot be aggravated.

The invention discloses a method for inducing cell copper death based on GK921 and application of the GK921, and relates to the technical field of biological medicine. The invention discloses a brand new function of inducing copper death by a known compound GK921 for the first time, and provides a brand new strategy for solving the problems of drug resistance and relapse of multiple myeloma. According to the method, target cells are treated with an effective amount of GK921, expression of copper ion transporter ATP7A in the cells is specifically reduced, copper ions are accumulated, and then typical copper death events such as iron-sulfur cluster protein reduction and DLAT protein oligomerization are caused. Experiments show that the GK921 can efficiently inhibit the activity of multiple myeloma cell lines and primary cells, and the IC50 value and the low toxicity to normal cells show excellent selectivity. On the basis, GK921 can be used for preparing a pharmaceutical composition for inducing copper death, and particularly has an important application prospect in treatment of multiple myeloma.

Provided in the present invention are a manganese ion transporter (MntP) protein mutant and a recombinant strain expressing the mutant for high-yield L-threonine production. The mutant has an amino acid sequence as shown in SEQ ID NO: 2, which is obtained by means of mutating glycine (G) at position 25 to aspartic acid (D) in a wild-type MntP protein sequence as shown in SEQ ID NO: 1. By means of homologous recombination, the mutant is introduced into an Escherichia coli strain, providing the constructed recombinant strain with an increased yield of L-threonine.

The invention discloses engineering saccharomycetes for selectively recovering waste valuable metals as well as a construction method and application of the engineering saccharomycetes. The tested microorganism is saccharomyces cerevisiae and comprises a gene for coding an exogenous metal ion transport protein, an inducible promoter and a terminator, and the promoter is galactose GAL1; and the terminator is CYC1 (Cytochrome CYC1). According to the invention, metal ion transport protein, metabolic pathway regulation, biomineralization and other synthetic biological tools are utilized, so that the recovery selectivity of valuable metals is improved; a biological system is mild in culture, can adapt to a relatively complex wastewater environment, and is beneficial to large-scale industrial operation; and a green and low-cost preparation mode is provided for preparation of high-added-value products. In a coexistence environment, the engineering yeast selectively recovers valuable metal Cd and synthesizes CdSe quantum dots of 92.20 mg / g dry yeast, and the CdSe quantum dots are 1.29 times that of wild saccharomyces cerevisiae. The system has the advantages of high selectivity, low cost, environmental friendliness and the like, and is suitable for metal resource utilization of electronic wastes, industrial wastewater and other scenes.

The invention relates to the technical field of solid-state batteries, in particular to a flame-retardant composite solid-state electrolyte and a preparation method and application thereof.The preparation method of the flame-retardant composite solid-state electrolyte comprises the steps that carbonic ester polymeric monomers, polymeric monomers containing amide groups and lithium salt are mixed, and a monomer solution is obtained; mixing the monomer solution with an inorganic electrolyte and an initiator to obtain a composite electrolyte precursor solution; and loading the composite electrolyte precursor solution on the polyimide porous membrane, and carrying out in-situ curing treatment to obtain the flame-retardant composite solid electrolyte. A polyimide porous membrane is used as a matrix, a carbonate polymeric monomer and an amide group-containing polymeric monomer are copolymerized to form an organic network, and a lithium salt for lithium ion transmission is compounded with an inorganic oxide solid electrolyte to realize organic-inorganic synergistic flame retardance; in addition, the inorganic electrolyte and a polymer chain form a three-dimensional skeleton structure, and a stable composite system is formed through oxygen vacancy anchoring.

To provide artificial expression constructs that selectively drive protein expression.SOLUTION: An artificial expression construct comprising a specific enhancer, a promoter, and a heterologous coding sequence, wherein in one aspect the heterologous coding sequence encodes an effector element or an expressible element, wherein the effector element comprises a reporter protein or a functional molecule, wherein the reporter protein comprises a fluorescent protein, An artificial expression construct is provided wherein the functional molecule comprises a functional ion transporter, an enzyme, a transcription factor, a receptor, a membrane protein, a cellular transport protein, a signaling molecule, a neurotransmitter, a calcium reporter, a channelrhodopsin, a CRISPR / CAS molecule, an editase, a guide RNA molecule, a microRNA, a homologous recombination donor cassette, or a designer receptor exclusively activated with a designer drug.SELECTED DRAWING: Figure 1

The present invention relates to sulfonyl carboxamide derivatives represented by formula (I): wherein R1 represents and aryl group, a cycloalkyl group, a heterocycloalkyl group, or polycyclic group; and R2 represents a bicyclic group. The invention further relates to a pharmaceutical composition comprising the compound of formula (I) in combination with one or more pharmaceutically acceptable excipients. This compound or composition specifically targets ion transporters, ensuring their proper funcitoning and preventing disorders associated with abnormal ion transport.

This invention discloses a genetically engineered bacterium producing high levels of butyric acid, its construction method, and its applications. The invention constructs a genetically engineered bacterium producing high levels of butyric acid by overexpressing a ferrous ion transporter protein in Clostridium. Compared to wild-type strains, the genetically engineered bacterium of this invention exhibits enhanced metabolic flux in reactions related to butyric acid synthesis, inhibits the allocation of carbon to byproduct pathways such as acetic acid and lactic acid, and maintains good growth and metabolic activity even under butyric acid stress, thereby prolonging the effective acid production time and improving the stability and final accumulation of butyric acid in the later stages of fermentation. In other words, the genetically engineered bacterium of this invention can increase the proportion of butyric acid in fermentation products under the same substrate conditions, reduce byproduct formation, and lower the difficulty and cost of downstream separation and purification. Furthermore, the genetically engineered bacterium of this invention is robust, suitable for scale-up and industrial applications, and beneficial for the biosynthesis and widespread application of butyric acid.

The invention provides that the expression and / or activity of metal ion transporter, such as a Ca2+ / Mn2+ transporter and secretory pathway calcium ATPase 1 (SPCA1) or SPCA2 is associated with the restoration and conservation of Golgi integrity in cells, and with the restoration of Golgi ion concentrations. Provided herein are methods of restoring or maintaining Golgi integrity and methods of modulating Golgi ion concentration in a cell including increasing the expression and / or activity of a metal ion transporter such as SPCA1 or SPCA2 in the cell. The invention further provides methods of treating diseases including neurodegenerative disease and Hailey Hailey disease including increasing the expression and / or activity of a metal ion transporter such as SPCA1 or SPCA2 protein in cells to restore or maintain Golgi integrity and Golgi ion concentration in the cell.

The present invention relates to sulfonyl carboxamide derivatives represented by formula (I):wherein R1 represents an aryl group, a cycloalkyl group, a heterocycloalkyl group, or polycyclic group; and R2 represents a bicyclic group. The invention further relates to a pharmaceutical composition comprising the compound of formula (I) in combination with one or more pharmaceutically acceptable excipients. This compound or composition specifically targets ion transporters, ensuring their proper functioning and preventing disorders associated with abnormal ion transport.